monoclon
antibodi
mab
long
provid
power
research
tool
virologist
understand
mechan
viru
entri
host
cell
antivir
immun
even
commerci
develop
human
human
mab
prophylaxi
preemptiv
acut
treatment
viral
infect
slow
surpris
new
antibodi
discoveri
tool
increas
speed
precis
potent
neutral
human
antivir
mab
identifi
longstand
barrier
antivir
mab
develop
antigen
variabl
circul
viral
strain
abil
virus
undergo
neutral
escap
overcom
deeper
insight
mechan
mab
action
engin
effector
function
also
improv
efficaci
antivir
mab
success
industri
academ
laboratori
coupl
ongo
chang
biomed
regulatori
environ
herald
era
commerci
develop
human
antivir
mab
therapi
like
surg
antibodi
bind
viral
target
high
affin
exquisit
specif
rational
behind
use
antivir
mab
immunotherapi
provid
potent
product
better
activ
polyclon
counterpart
virusneutr
human
mab
isol
nonimmun
immun
sourc
use
wide
rang
recent
develop
antibodi
isol
technolog
pioneer
studi
laboratori
robert
koch
demonstr
administr
sheep
antiserum
diphtheria
toxin
girl
die
diphtheria
led
rapid
recoveri
within
hour
ultim
surviv
earli
sera
individu
recov
rubeola
measl
use
prevent
infect
highli
contagi
viru
sinc
strategi
administ
sera
survivor
variou
viral
epidem
treatment
acut
cytopath
viral
diseas
wide
practic
tabl
improv
qualiti
fraction
human
immunoglobulin
led
widespread
use
intramuscular
inject
pool
human
immunoglobulin
prevent
treat
viral
infect
rubella
hepat
better
protect
less
sever
reaction
sera
earli
sever
immunoglobulin
g
igg
prepar
licens
intraven
use
prevent
treat
viral
diseas
permit
much
increas
amount
immunoglobulin
administ
mani
product
still
market
today
includ
gener
pool
human
igg
prevent
measl
hepat
well
hyperimmun
human
igg
prepar
cytomegaloviru
cmv
respiratori
syncyti
viru
rsv
hepat
b
viru
hbv
hepat
c
viru
hcv
rabi
vaccinia
varicellazost
viru
vzv
west
nile
viru
wnv
box
tabl
polyclon
antibodi
respons
gener
numer
epitop
differ
viral
antigen
infect
serumderiv
polyclon
antibodi
prepar
contain
larg
divers
popul
antibodi
includ
neutral
antibodi
nab
multipl
epitop
differ
nab
within
polyclon
antibodi
prepar
bind
distinct
epitop
provid
strong
antivir
activ
due
addit
even
synergist
effect
neutral
howev
disadvantag
associ
polyclon
antibodi
product
vast
major
constitu
virusspecif
antibodi
nonneutr
direct
epitop
nativ
viral
surfac
protein
antibodi
bind
interfer
viral
infect
wherea
other
direct
intern
denatur
incomplet
translatedassembl
protein
releas
infect
cell
nonn
viral
surfac
protein
misfold
protein
incorpor
onto
viru
shed
circul
also
elicit
nonneutr
antibodi
disadvantag
use
polyclon
antibodi
product
immun
serum
includ
batchtobatch
variat
risk
pathogen
transmiss
sever
excel
review
passiv
antibodi
therapi
infecti
diseas
avail
articl
focus
recent
advanc
human
mab
engin
enabl
isol
character
potent
human
antivir
antibodi
unpreced
speed
also
describ
perceiv
limit
antivir
mab
therapi
result
antigen
variabl
circul
strain
abil
virus
undergo
neutral
escap
overcom
advancescombin
greater
understand
antivir
mechan
action
fc
effector
engin
improv
human
mous
model
infecti
diseaseswil
acceler
translat
research
candid
antivir
mab
foster
new
era
passiv
immunotherapi
among
approach
display
technolog
differ
microorganismsinclud
phage
yeast
bacteria
virusesar
use
display
repertoir
singlechain
variabl
antibodi
fragment
scfv
antigenbind
fragment
fab
domain
antibodi
dab
surfac
enrich
isol
iter
cycl
pan
fig
display
technolog
includ
ribosom
mammalian
cell
display
also
report
although
phage
displaybas
select
current
use
often
develop
human
mab
select
method
often
complementari
fundament
select
bias
difficult
control
pan
exampl
recent
studi
demonstr
immun
scfv
librari
display
yeast
fulli
express
phage
select
scfv
identifi
phage
also
twice
mani
novel
antibodi
common
observ
differ
nab
identifi
use
differ
display
technolog
suggest
antibodi
fold
effici
posttransl
modif
epitop
access
may
influenc
outcom
select
addit
method
present
antigen
bait
pan
may
affect
number
distribut
avail
neutral
epitop
purifi
envelop
glycoprotein
either
monomer
oligomer
form
viral
particl
two
type
antigen
commonli
use
bait
pan
technolog
human
immunoglobulin
transgen
mice
use
gener
human
mab
sever
acut
respiratori
syndrom
coronaviru
sarscov
rabi
fig
techniqu
involv
clone
human
mabexpress
b
cell
isol
immun
transgen
mice
human
miniimmunoglobulin
gene
locu
knockedin
replac
mous
immunoglobulin
gene
locu
immun
respons
transgen
mice
sometim
less
robust
strain
use
gener
mous
mab
immun
antibodi
screen
often
requir
anoth
techniqu
involv
use
human
memori
bcell
sourc
human
mab
fig
memori
bcell
obtain
blood
individu
recov
viru
infect
cell
transform
epsteinbarr
viru
ebv
presenc
polyclon
memori
bcellactiv
agent
irradi
mononuclear
cell
cpg
oligonucleotid
tolllik
receptor
ligand
greatli
increas
transform
effici
therebi
obviat
need
fusion
step
gener
hybrid
cell
hybridoma
techniqu
memori
bcell
isol
blood
individu
recov
sarscov
avian
influenza
infect
immort
use
method
produc
nab
virus
addit
isol
screen
technolog
increas
access
differ
immun
repertoir
like
increas
rescu
therapeut
antibodi
make
minor
contribut
typic
antibodi
respons
exampl
memori
bcell
librari
may
provid
richer
sourc
antibodi
viral
pathogen
use
bone
marrow
aspir
peripher
blood
bcell
construct
nonimmun
immun
librari
lastli
human
murin
mab
oldest
tool
gener
therapeut
human
mabsi
still
use
particularli
murin
mab
extens
character
desir
antivir
properti
andor
superior
fulli
human
mab
hard
obtain
graft
complementar
determin
region
cdr
residu
togeth
minim
key
framework
residu
variabl
region
rodent
donor
mab
onto
acceptor
human
antibodi
framework
human
allow
bind
affin
specif
parent
mab
retain
reduc
risk
immunogen
fig
viabl
approach
classic
simplest
strategi
human
among
mani
avail
strategi
graft
specif
determin
residu
support
advanc
genet
engin
threedimension
model
protein
structur
fact
nearli
half
us
food
drug
administr
fda
approv
therapeut
mab
human
antibodi
testifi
safeti
toler
human
viral
neutralizationth
abil
antibodi
bind
inactiv
virusi
test
vitro
defin
experiment
condit
nab
identifi
manner
also
protect
anim
vivo
although
host
protect
complex
involv
interact
antibodi
cell
molecul
innat
immun
system
therefor
better
understand
viral
neutral
mechan
definit
enrich
antivir
strategi
develop
reader
refer
sever
excel
review
viral
neutral
mechan
model
describ
briefli
virus
categor
envelop
nonenvelop
accord
whether
possess
lipid
membran
although
entri
mechan
differ
envelop
nonenvelop
virus
share
main
step
viru
entri
begin
attach
cellsurfac
receptor
end
deliveri
viral
genet
materi
cytoplasm
fusion
viral
cellular
membran
basic
entri
mode
envelop
virus
influenza
viru
extens
studi
wherea
nonenvelop
virus
penetr
cell
either
lyse
membran
creat
porelik
structur
membran
although
mechan
membran
penetr
nonenvelop
virus
poorli
understood
conform
chang
differ
amino
acid
sequenc
differ
subclass
igg
human
affect
bind
affin
differ
class
activ
proinflammatori
inhibitori
antiinflammatori
receptor
likewis
differ
sequenc
attach
oligosaccharid
may
critic
antibodi
function
remov
termin
sialic
acid
result
increas
antiinflammatori
activ
refin
commerci
immunoglobulin
prepar
regard
igg
subclass
oligosaccharid
content
may
result
polyclon
immunoglobulin
product
improv
antivir
activ
viral
entri
protein
import
envelop
nonenvelop
virus
enter
cell
trigger
conform
chang
includ
receptor
bind
receptorcoreceptor
bind
exposur
low
ph
within
endocyt
pathway
mab
inhibit
viral
infect
sever
differ
mechan
parallel
step
virus
take
enter
cell
fig
directli
block
viru
attach
target
cell
interf
virusreceptor
interact
fig
nab
site
ref
receptorbind
site
influenza
hemagglutinin
receptor
bind
domain
sarscov
tabl
goal
also
achiev
direct
antibodi
viru
receptor
andor
coreceptor
exemplifi
andor
ccmotif
receptor
receptor
mab
respect
develop
prophylaxi
treatment
fig
tabl
kati
risvicari
viral
protein
trigger
low
ph
endosom
activ
viral
endosom
membran
fusion
mab
may
block
conform
chang
andor
requisit
interact
viral
endosom
membran
requir
fusion
fig
exampl
antihemagglutinin
mab
lack
hemagglutinin
inhibit
activ
block
receptor
bind
neutral
infect
influenza
viru
interf
low
phinduc
conform
chang
hemagglutinin
molecul
result
inhibit
fusion
viral
replic
mab
also
block
fusion
cell
membran
postbindingprefus
stage
fig
virus
bind
receptor
receptor
coreceptor
serv
attach
point
well
trigger
conform
chang
allow
membran
fusion
exampl
interact
trigger
conform
chang
envelop
result
exposur
transient
bind
site
coreceptor
turn
promot
addit
conform
chang
allow
insert
fusion
peptid
target
cell
membran
initi
membran
fusion
viral
entri
host
cell
mab
extern
proxim
membran
region
interfer
conform
chang
need
membran
fusion
inhibit
releas
progeni
viru
anoth
mechan
action
exampl
mab
influenza
virion
surfac
neuraminidas
prevent
releas
virion
infect
cell
surfac
fig
sever
model
neutral
variou
virus
antibodi
propos
one
simpl
occup
coat
model
gener
corrobor
multihit
neutral
hypothesi
sometim
refer
multihit
model
accord
model
neutral
occur
suffici
number
avail
function
protein
virion
occupi
antibodi
lead
inhibit
viral
attach
interfer
fusion
process
support
neutral
studi
variou
virus
show
linear
relationship
viru
size
number
antibodi
requir
neutral
recent
studi
dissect
stoichiometri
antibodi
neutral
wnv
show
lower
occup
antibodydepend
enhanc
ade
box
viru
infect
domin
wherea
higher
concentr
neutral
ensu
studi
also
support
occup
model
show
cumul
function
outcom
determin
interplay
antibodi
affin
epitop
access
anoth
propos
model
neutral
critic
bind
site
model
accord
model
antibodi
coat
virion
alon
requisit
neutral
certain
bind
site
critic
neutral
wherea
other
model
compat
singleor
multihit
theori
neutral
note
howev
consider
disagr
area
remain
common
appli
virusantibodi
kati
risvicari
neutral
interact
despit
predict
model
could
lead
better
design
therapeut
antibodi
exampl
occup
model
predict
larger
virion
possess
avail
epitop
requir
bound
antibodi
neutral
importantli
higher
affin
antibodi
neutral
greater
efficaci
regardless
mechan
best
strategi
develop
potent
nab
ultrahigh
bind
affin
target
critic
neutral
site
hierarchi
neutral
site
target
determin
analyz
epitop
access
number
eas
neutral
escap
variabl
circul
strain
natur
product
immun
system
antibodi
interact
immun
cell
protein
fulfil
antivir
function
numer
immunemedi
mechan
viru
clearanc
describ
exampl
fc
region
mediat
complement
bind
deposit
free
virion
caus
direct
virotox
effect
inhibit
viru
bind
cell
fig
complement
receptor
bind
antibodyandor
complementco
virion
lead
phagocytosi
subsequ
inactiv
virion
intracellular
compart
phagocyt
antibodydepend
cellmedi
cytotox
adcc
natur
killer
cell
anoth
mechan
infect
cell
clear
rel
contribut
differ
immunemedi
clearanc
mechan
studi
transgen
mice
lack
complement
complement
receptor
recent
studi
demonstr
receptor
complement
bind
import
antibodymedi
protect
vivo
final
augment
immun
respons
also
goal
control
chronic
viral
infect
molecul
glucocorticoidinduc
tumor
necrosi
factor
tnf
receptor
express
subset
cell
includ
regulatori
cell
effector
cell
suppress
effector
cellfunct
respons
viral
antigen
mab
glucocorticoidinduc
tnf
receptor
blunt
viru
replic
block
inhibit
effector
tcellfunct
andor
decreas
threshold
effector
cell
respond
viral
antigen
likewis
recent
studi
demonstr
pathway
member
famili
inhibitori
immunoregulatori
molecul
play
major
role
regul
tcell
exhaust
chronic
lymphocyt
choriomening
viru
lcmv
infect
antibodi
use
block
pathway
vivo
chronic
lcmv
infect
virusspecif
tcell
respons
enhanc
anoth
inhibitori
regul
famili
cytotox
lymphocyt
antigen
select
upregul
hivspecif
tcell
coexpress
find
mab
blockad
vitro
augment
hivspecif
tcell
function
suggest
mabmedi
immun
modul
target
may
also
provid
clinic
benefit
individu
infect
hiv
despit
therapeut
potenti
mabmedi
augment
immun
respons
control
chronic
viral
infect
worth
note
recent
tragic
human
trial
mab
human
highlight
potenti
risk
associ
manipul
immunolog
respons
care
plan
preclin
studi
nonhuman
primat
clearli
requir
identifi
potenti
problem
prevent
prematur
test
potent
mab
human
studi
tabl
summar
antivir
mab
current
clinic
develop
describ
technolog
use
isol
virus
group
acut
cytopath
acut
cytopathiclat
reactiv
chronic
noncytopath
acut
cytopath
virus
caus
excess
damag
infect
tissu
must
control
rapidli
host
surviv
herp
virus
remain
latent
primari
infect
reactiv
lead
acut
cytopath
effect
tissu
damag
particularli
immunocompromis
individu
thu
character
acut
cytopathiclat
reactiv
poorli
noncytopath
virus
usual
persist
lifetim
host
first
categori
especi
noteworthi
fda
approv
licens
palivizumab
synagi
neutral
human
murin
mabfor
prevent
seriou
rsv
pulmonari
infect
highrisk
pediatr
individu
report
safeti
efficaci
palivizumab
clinic
trial
involv
infant
bronchopulmonari
dysplasia
infant
born
prematur
week
gestat
age
children
hemodynam
signific
congenit
heart
diseas
favor
human
murin
mab
remain
fdaapprov
antivir
antiinfecti
agent
antibodi
market
motavizumab
second
gener
ultrahigh
affin
matur
variant
palivizumab
markedli
reduc
lung
rsv
titer
cotton
rat
reduc
rsv
titer
human
upper
respiratori
track
effect
predecessor
compar
palivizumab
motavizumab
greater
bind
avid
rsv
f
protein
sixfold
faster
associ
rate
slower
dissoci
rate
improv
potenc
motavizumab
thought
larg
due
fact
associ
rate
faster
palivizumab
recent
phase
placebocontrol
studi
show
motavizumab
reduc
rsv
hospit
lower
respiratori
infect
requir
outpati
manag
two
compani
antirabi
mab
develop
postexposur
prophylaxi
infect
one
enter
phase
studi
two
firm
conduct
phase
studi
mab
wnv
treatment
neurolog
diseas
antisarscov
mab
earlier
stage
develop
tabl
among
acut
cytopathiclat
reactiv
group
two
mab
commerci
develop
treat
cmv
diseas
phase
studi
underway
one
antibodi
treat
cmv
retin
individu
infect
cmv
pneumonia
bone
marrow
transplantationrecipi
mab
envelop
glycoprotein
iii
vzv
also
preclin
develop
treatment
vzv
diseas
rituximab
direct
approv
fda
treat
nonhodgkin
lymphoma
rheumatoid
arthriti
phase
studi
treat
ebvassoci
posttranspl
lymphoprolif
diseas
interstiti
pneumonia
clinic
develop
categori
chronic
noncytopath
virus
extens
includ
mab
direct
hcv
clinic
advanc
mab
current
phase
trial
treatment
optim
background
therapi
three
mab
develop
direct
coreceptor
two
three
mab
subtyp
fc
region
interact
poorli
complement
receptor
express
immun
cell
use
allow
antibodi
act
receptorcoreceptor
block
agent
without
elimin
target
cell
immunemedi
clearanc
mechan
anoth
interest
mab
develop
treatment
hcv
coinfect
direct
anion
phospholipid
princip
phosphatidylserin
becom
expos
surfac
viru
infect
cell
vast
effort
span
academ
laboratori
worldwid
involv
differ
virus
least
viru
famili
underway
develop
human
antivir
mab
tabl
notabl
major
academ
public
report
sinc
research
involv
broad
rang
screen
isol
technolog
direct
toward
isol
character
nab
envelop
protein
immun
repertoir
use
isol
antibodi
vari
consider
mani
case
antibodi
use
research
tool
better
understand
mechan
viru
entri
neutral
studi
also
aim
identifi
character
neutral
epitop
glycoprotein
sever
laboratori
perform
preclin
prophylaxi
postvir
challeng
mab
protect
studi
rodent
wherea
similar
preclin
studi
ebola
involv
nonhuman
primat
steril
protect
viru
infect
diseas
modif
seen
anim
viru
challeng
treatment
high
concentr
administ
antibodi
import
mechan
diseas
pathogenesi
uncov
effort
exemplifi
failur
nab
affect
cours
ebola
viru
infect
monkey
contrast
protect
effect
guinea
pig
potent
neutral
activ
vitro
result
neutral
mab
studi
use
extens
guid
vaccin
design
particular
effort
direct
toward
mab
like
fuel
clinic
develop
pipelin
research
effort
continu
numer
studi
hbv
rsv
virus
demonstr
synergist
andor
addit
effect
combin
two
mab
viru
neutral
accordingli
one
excit
recent
advanc
field
develop
mab
cocktail
prophylaxi
treatment
viral
infect
address
sever
level
one
major
risk
target
one
epitop
viral
pathogen
singl
mab
exampl
occup
model
multihit
theori
neutral
propos
obtain
suffici
antibodi
densiti
surfac
viral
pathogen
critic
factoroften
import
epitop
recognizedneed
viral
neutral
elimin
may
possibl
case
singl
epitop
recogn
achiev
one
epitop
occupi
viru
surfac
equal
import
target
epitop
may
conserv
strain
pathogen
even
epitop
conserv
select
pressur
antibodi
may
drive
neutral
escap
viru
point
mutat
fig
combin
two
mab
two
neutral
epitop
shown
fig
nonoverlap
cover
vast
major
circul
strain
prevent
neutral
escap
clinic
advanc
mab
area
rabi
box
fact
phase
clinic
trial
current
underway
mab
cocktail
without
prior
clinic
test
mab
separ
underscor
fda
recognit
mab
cocktail
may
provid
equal
better
antivir
activ
equival
avail
commerci
immunoglobulin
product
deriv
human
hyperimmun
serum
monoclon
antibodi
cocktail
may
also
fill
need
gap
global
shortag
hyperimmun
serum
whose
suppli
avail
sometim
limit
technolog
develop
recombin
human
polyclon
antibodi
viral
pathogen
report
combin
clone
antibodi
singl
antigenspecif
immun
bcell
sitespecif
integr
antibodyproduc
cell
result
uniform
master
cell
bank
manufactur
polyclon
antibodi
defin
specif
major
advantag
antivir
mab
therapi
long
serum
halflif
often
day
confer
prolong
vivo
protect
anim
studi
demonstr
efficaci
infect
diseas
progress
number
viral
pathogen
singl
dose
mab
given
prophylact
earli
treatment
infect
respect
singledos
treatment
strategi
may
ideal
prophylaxi
treatment
acut
cytopath
respiratori
viru
infect
sarscov
avian
influenza
even
smallpox
provid
suffici
serum
nab
level
achiev
intraven
intramuscular
subcutan
administr
human
antivir
mab
inhal
therapi
anoth
intrigu
possibl
sever
anim
studi
correl
prophylact
administr
mab
concentr
serum
vitro
neutral
titer
serum
quantit
measur
eg
protect
requir
tcid
tissu
cultur
infect
dose
vitro
neutral
titer
dilut
serum
type
quantit
analysi
could
establish
phase
studi
therapeut
antivir
mab
first
consider
use
antivir
mab
immunotherapi
outbreak
set
determin
whether
circul
viru
sensit
neutral
mab
hand
approach
propos
laboratori
respons
potenti
futur
sar
outbreak
involv
obtain
earli
biolog
specimen
suspect
case
eg
nasalpharyng
aspir
respiratori
secret
rapidli
perform
pcr
amplif
dna
sequenc
viral
protein
gene
segment
encod
mab
epitop
data
would
compar
preconstruct
sensitivityresist
map
mab
base
analys
natur
occur
well
focus
random
mutagenesi
amino
acid
within
epitop
vitro
neutral
studi
mutant
viral
protein
pseudotyp
report
virus
way
guid
antivir
mab
passiv
immunotherapi
could
institut
realist
expect
clinic
efficaci
furthermor
respiratori
viru
outbreak
set
prevent
strategi
could
stratifi
accord
highrisk
exposur
priorit
treatment
famili
member
healthcar
worker
first
respond
goal
would
provid
immedi
protect
even
virusinfect
individu
addit
time
could
obtain
mount
effect
nativ
antivir
immun
respons
andor
administ
antivir
drug
inhibit
viru
replic
postentri
phase
immunocompromis
individu
elderli
individu
comorbid
medic
risk
factor
seriou
diseaseal
may
weaken
immun
systemsar
also
like
good
candid
passiv
immunotherapi
epidem
control
strategi
includ
passiv
ring
immun
could
appli
decreas
transmiss
reduc
contact
although
past
centuri
wit
tremend
progress
develop
polyclon
antivir
immunotherapi
pace
antivir
mab
discoveri
never
greater
advanc
fuel
new
antibodi
screen
isol
technolog
better
understand
construct
use
nonimmun
immun
antibodi
repertoir
grow
interest
virolog
emerg
new
viral
pathogen
also
kept
field
ablaz
part
global
box
antibodydepend
enhanc
ade
mechan
virusspecif
antibodi
enhanc
viral
entri
intoand
case
replic
inmonocytesmacrophag
granulocyt
cell
interact
andor
complement
receptor
ade
demonstr
vitro
use
antidengu
antiwnv
antibodi
cell
bear
receptor
well
monkey
infus
antidengu
antibodi
ade
propos
mechan
respons
dengu
hemorrhag
fever
dengu
shock
syndrom
two
clinic
condit
frequent
seen
patient
infect
second
heterotrop
infect
infant
matern
transfer
antidengu
antibodi
infect
dengu
viru
flaviviru
induc
broadli
crossreact
weakli
neutral
well
nonneutr
antibodi
ade
occur
concentr
neutral
antibodi
fall
stoichiometr
threshold
neutral
becom
subneutr
preexist
subneutr
nonneutr
antibodi
infect
dengu
viru
form
complex
bind
receptorbear
cell
lead
increas
viru
uptak
replic
world
travel
increas
risk
rapid
transmiss
dissemin
new
viral
diseas
also
grow
realiz
viral
pathogen
optim
diseas
prevent
manag
may
achiev
tradit
vaccin
popul
risk
rather
institut
local
region
intern
public
healthcar
measur
earli
prevent
contain
infect
success
demonstr
case
sar
situat
frequenc
viral
infect
low
protect
could
provid
passiv
immunotherapi
period
highrisk
exposur
avoid
potenti
side
effect
vaccin
caus
untoward
morbid
even
rare
mortal
exemplifi
yellow
fever
vaccineassoci
viscerotrop
diseas
moreov
antivir
vaccin
high
titer
broadli
neutral
antibodi
either
elicit
titer
wane
time
either
case
nab
titer
may
protect
time
viral
challeng
may
occur
year
vaccin
anoth
possibl
risk
ade
vaccin
virus
enhanc
diseaseassoci
clinic
syndrom
demonstr
andor
postul
occur
antibodi
titer
fall
neutral
threshold
box
case
domin
antibodi
respons
may
stronger
vaccin
strain
secondari
viral
challeng
stain
phenomenon
known
origin
antigen
sin
exampl
use
shortterm
passiv
immunotherapi
high
titer
nab
readili
achiev
may
provid
tangibl
advantag
vaccin
paramount
import
technolog
improv
develop
antivir
mab
therapeut
underst
antibodyenvelop
cocrystallograph
studi
provid
import
structur
detail
atom
level
serv
guid
understand
mechan
neutral
neutral
escap
combin
genet
mutagenesi
silico
model
mab
bind
improv
mab
affin
neutral
activ
technolog
improv
horizon
includ
incorpor
neutral
assay
earlier
screen
platform
well
broaden
specif
exist
nab
prevent
neutral
escap
gener
broad
crossviralstrain
neutral
activ
improv
antivir
activ
also
seen
modif
fc
effector
function
introduc
fc
glycoengin
improv
adcc
activ
certain
viral
ill
dengu
viru
infect
alter
fc
region
explor
way
reduc
elimin
ade
develop
newer
gener
human
mice
host
human
immun
cell
like
allow
better
understand
complex
role
fc
effector
function
viral
clearanc
whether
fab
arm
exchang
subclass
use
enhanc
antivir
activ
mab
vivo
crosslink
neutral
epitop
andor
enabl
bispecif
target
virus
immun
effector
cell
explor
particularli
excit
area
current
explor
use
human
antibodi
viral
receptor
coreceptor
sever
recent
discov
includ
transferrin
receptor
receptor
new
world
hemorrhag
fever
arenavirus
coreceptor
hcv
potenti
advantag
directli
block
cellular
receptorcoreceptor
mab
like
block
viru
entri
genet
divers
circul
strain
exampl
antibodi
block
sever
differ
new
world
arenavirus
mab
block
broad
rang
rtropic
virus
express
differ
envelop
glycoprotein
nevertheless
although
epitop
highli
conserv
mutat
natur
rabi
viru
isol
anoth
human
nab
develop
complement
nab
recogn
distinct
epitop
complementarili
neutral
escap
mutant
global
coverag
natur
rabi
viru
isol
cocktail
demonstr
spectrum
vitro
neutral
studi
escap
virus
longer
obtain
vitro
select
pressur
cocktail
syrian
hamster
anim
studi
show
cocktail
safe
efficaci
altern
hyperimmun
rabi
immunoglobulin
rabi
post
exposur
prophylaxi
figur
human
mab
combin
therapi
two
separ
neutral
epitop
preval
envelop
glycoprotein
circul
viru
shown
neutral
antibodi
recogn
neutral
epitop
ei
nei
eii
neii
circul
strain
row
combin
provid
broad
neutral
activ
prevent
neutral
escap
natur
variant
neii
neutral
escap
mutant
still
recogn
row
likewis
natur
variant
nei
neutral
escap
mutant
still
recogn
row
avail
use
maintain
two
nab
circul
variant
virus
rare
would
combin
requir
row
kati
risvicari
antibodi
blockad
cell
surfac
receptor
may
pose
unforeseen
risk
exampl
although
promot
leukocyt
traffick
brain
improv
surviv
follow
wnv
infect
defici
increas
risk
symptomat
wnv
infect
despit
progress
sever
formid
challeng
remain
although
explos
growth
commerci
exploit
therapeut
antibodi
applic
prevent
andor
treatment
infecti
diseas
viral
infect
lag
behind
diseasetyp
scientif
challeng
specif
develop
mab
antiinfecti
agent
well
clinic
market
challeng
clearli
temper
commerci
interest
area
potenti
commerci
obstacl
includ
concern
antigen
escap
viral
variabl
manag
engin
higheraffin
mab
use
mab
cocktail
low
preval
treatabl
viral
diseas
grow
pipelin
smallmolecul
inhibitor
viru
replic
competit
effect
antivir
vaccin
enter
market
could
rapidli
replac
need
passiv
infus
mab
anoth
potenti
obstacl
rel
short
durat
viral
ill
make
less
attract
commerci
target
diseas
cancer
chronic
inflammatori
autoimmun
diseas
requir
longer
mab
treatment
cycl
even
preval
commerci
antivir
mab
treatment
may
increas
potent
mab
optimum
effector
capabl
combat
identifi
addit
like
antivir
mab
use
also
increas
frequenc
combin
smallmolecul
drug
inhibit
postentri
step
viru
life
cycl
combin
therapi
certainli
commerci
path
taken
antibodi
block
hcv
hiv
infect
chronic
monthli
treatment
mab
part
drug
regimen
would
provid
strong
incent
particip
biopharmaceut
compani
develop
antivir
mab
product
abund
antivir
mab
pipelin
establish
track
record
manufactur
clinic
safeti
need
compani
compet
marketplac
suggest
antibodi
drug
like
becom
increas
part
clinician
armamentarium
notwithstand
sanguin
view
growth
potenti
antivir
antibodi
therapeut
zeal
must
temper
realiti
cost
intens
mab
product
alreadi
overtax
healthcar
system
provid
strateg
prophylaxi
treatment
stratif
plan
passiv
immunotherapi
could
use
viru
outbreak
set
plan
would
substanti
limit
number
dose
would
need
stockpil
viral
diseas
treatment
stratif
possibl
howev
cost
mab
product
decreas
mab
manufactur
facil
capabl
largescal
product
rise
product
mammalian
cell
cultiv
bioreactor
one
gram
per
liter
sever
case
improv
titer
similar
process
realiz
newer
method
mab
manufactur
improv
product
advanc
dna
deliveri
integr
host
cell
engin
medium
optim
effici
select
gene
amplif
celllin
screen
system
acceler
trend
plant
biopharm
mab
also
offer
promis
ensur
cheaper
mass
product
mab
global
healthrel
viral
diseas
rabi
inde
vision
largescal
biopharm
antivir
mab
plant
throughout
develop
world
could
support
growth
vital
area
way
one
